ClinicalTrials.gg
CompletedNCT00133198Updated Nov 8, 2013

Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)

A Phase 3 interventional study of Pramipexole in Restless Legs Syndrome, sponsored by Boehringer Ingelheim. Completed at 44 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-11-08.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
345
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing pramipexole in Restless Legs Syndrome — none open to participants now, 1 under way, none of them phase 3. Pramipexole · Restless Legs Syndrome.

Enrollment
5th of 17
345 · median 154
Started
2004
with 2 others
Phase 3
6 of 17
none open now
Registered
1st of 17
by date
Lead sponsor
12 of 17
Boehringer Ingelheim

Among the 17 studies testing pramipexole in Restless Legs Syndrome, this one is the 5th largest by enrollment, is one of 3 that started in 2004, is one of 6 in phase 3, and was the 1st registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 17 studies testing pramipexole in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing pramipexole in Restless Legs Syndrome as a file.
02

Study summary

A 12 week clinical trial was conducted in the United States in order to compare pramipexole (Mirapex®) versus placebo for the ability to reduce the symptoms of restless legs syndrome in adult subjects.

03

Conditions studied

  • Restless Legs Syndrome
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
This record does not list eligibility criteria. Contact the study team before assuming you do or do not qualify.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
345 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in the total score of RLSRS (Restless Legs Syndrome rating scale for severity) of the IRLSSG (International Restless Legs Syndrome Study Group)

    Time frame: week 12

  2. CGI-I (CGI-Improvement)

    Time frame: week 12

Secondary outcomes

  1. RLSRS response (≥50% reduction from baseline in RLSRS)

    Time frame: at week 4, 6 and 12

  2. CGI-I responder analysis

    Time frame: at week 4, 6 and 12

  3. Change from baseline in CGI-Severity

    Time frame: at week 4, 6 and 12

  4. CGI-therapeutic effect

    Time frame: at week 4, 6 and 12

  5. CGI-Side effects

    Time frame: at week 4, 6 and 12

  6. Patient Global Impression (PGI)

    Time frame: at week 1-4, 6 and 12

  7. Visual analogue scales to assess RLS severity before sleep onset, during night and during day, and satisfaction with sleep

    Time frame: at week 4, 6 and 12

  8. Change from baseline in Epworth sleepiness scale (ESS)

    Time frame: at week 4, 6 and 12

  9. Change from baseline in RLS-QOL (Johns Hopkins Restless Legs Syndrome Quality of Life questionnaire)

    Time frame: at week 6 and 12

  10. Change from baseline in Augmentation Severity Rating Scale of IRLSSG

    Time frame: at week 6 and 12

  11. Change in systolic and diastolic blood pressure (after 5 minutes supine and subsequently after 1 minute standing)

    Time frame: week 12

  12. Change in pulse rate (palpation after 5 minute supine and subsequent after 1 minute standing)

    Time frame: week 12

  13. Change in routine laboratory tests

    Time frame: week 12

  14. Change in Physical examinations including eye examinations with ophthalmoscopic retinal eye examinations and a full skin dermatologic examination

    Time frame: week 12

  15. Change in Electrocardiogram

    Time frame: 12 weeks

  16. Incidence of Adverse evens (including withdrawal symptoms and rebound symptoms)

    Time frame: up to 93 days

  17. Concomitant medication reporting

    Time frame: 12 weeks

  18. Early withdrawal phenomena

    Time frame: 12 weeks

  19. Assessment of sudden onset of sleep (SOOS)

    Time frame: up to 93 days

07

Study locations

44 sites
  • Pivotal Research Centers
    Peoria, Arizona 85381, United States
  • Mayo Clinic - Scottsdale
    Scottsdale, Arizona 85259, United States
  • Boehringer Ingelheim Investigational Site
    Fountain Valley, California 92708, United States
  • HealthQuest Clinical Trials Research
    San Diego, California 92123, United States
  • Stanford Sleep Clinic
    Stanford, California 94305-5730, United States
  • Adult CF Center
    Denver, Colorado 80206, United States
  • University of Colorado Health Sciences Center
    Denver, Colorado 80262, United States
  • CNI Movement Disorders Center
    Englewood, Colorado 80113, United States
  • George Washington University Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • PAB Clinical Research
    Brandon, Florida 33511, United States
  • Broward Research Group
    Pembroke Pines, Florida 33026-1956, United States
  • Clinical Research Group of St Petersburg
    St.Petersburg, Florida 33707, United States
  • Cleveland Clinic Florida- Department of Neurology
    Weston, Florida 33331, United States
  • 5671 Peachtree Dunwoody Road
    Atlanta, Georgia 30342, United States
  • Atlanta Pulmonary Group, LLC
    Atlanta, Georgia 30342, United States
  • Movement Disorders Clinic
    Augusta, Georgia 30912, United States
  • Sleepmed, Inc
    Macon, Georgia 31201, United States
  • University of Iowa Health Care
    Iowa City, Iowa 52242-1053, United States
  • Mid America NeuroScience Institute
    Lenexa, Kansas 66214, United States
  • Boehringer Ingelheim Investigational Site
    Baton Rouge, Louisiana 70808, United States
  • Center for Sleep and Wake Disorders
    Chevy Chase, Maryland 20815, United States
  • 170 Thomas Johnson Dr, Suite 100
    Frederick, Maryland 21702, United States
  • Sleep Health Centers
    Newton Center, Massachusetts 02459, United States
  • Henry Ford Hospital - Sleep Disorders and Research Center
    Detroit, Michigan 48202, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota 55415, United States
  • Sleep Disorders Center
    Jackson, Mississippi 39216, United States
  • Sleep Medicine Center
    St.Louis, Missouri 63108, United States
  • Lovelace Scientific Resources
    Albuquerque, New Mexico 87108, United States
  • Winthrop Sleep Disorders Center
    Mineola, New York 11501, United States
  • 932 Morreene Road #264
    Durham, North Carolina 27705, United States
  • Raleigh Neurology Associates
    Raleigh, North Carolina 27607, United States
  • Wilmington Health Associates
    Wilmington, North Carolina 28401, United States
  • Attn: Dr. David Mayleben
    Cincinnati, Ohio 45219, United States
  • Metrohealth Medical Center
    Cleveland, Ohio 44109, United States
  • Ohio Sleep Medicine Institute
    Dublin, Ohio 43017, United States
  • Attn: Controller/Grants & Contracts Accounting
    Oklahoma City, Oklahoma 73190-3046, United States
  • Center For Sleep Medicine
    Lafayette Hill, Pennsylvania 19444, United States
  • The Arthritis Group
    Philadelphia, Pennsylvania 19152, United States
  • Boehringer Ingelheim Investigational Site
    Columbia, South Carolina 29201, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Sleep Associates
    Plano, Texas 75093, United States
  • 1500 N. Bearegard St, #300
    Alexandria, Virginia 22311, United States
  • Lynchburg Pulmonary Associates, Inc.
    Lynchburg, Virginia 24501, United States
  • Eastern Virginia Medical School
    Norfolk, Virginia 23507, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of Feb 2005 and a completion of Feb 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2005
First posted
Aug 23, 2005
Start
Apr 2004
Primary completionActual
Feb 2005
Completion
Feb 2005
Last update
Nov 8, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00133198
First posted
Aug 23, 2005
Start date
Apr 2004
Primary completion
Feb 2005
Completion
Feb 2005
Last update
Nov 8, 2013

Study contacts

Boehringer Ingelheim Study Coordinator
study chair · B.I. Pharmaceuticals,Inc./Ridgefield
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion